X
<

What Drove Eli Lilly in 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 2
What Drove Eli Lilly in 3Q17? PART 2 OF 12

How Eli Lilly’s Cardiovascular Portfolio Performed

Adcirca revenue trends

In 3Q17, Eli Lilly’s (LLY) Adcirca generated revenues of $25.4 million, a ~14% increase on a year-over-year (or YoY) basis and 11% growth on a quarter-over-quarter basis.

Adcirca reported revenues of $69.2 million in the first nine months of 2017. Adcirca generated revenues of $14.9 million and $54.3 million, respectively, from the US and international markets. Adcirca is used for the treatment of pulmonary arterial hypertension.

How Eli Lilly’s Cardiovascular Portfolio Performed

Interested in AZN? Don't miss the next report.

Receive e-mail alerts for new research on AZN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Cialis revenue trends

In 3Q17, Cialis generated revenues of $564.9 million, a ~4% decline on a YoY basis and a 10% decline on a quarter-over-quarter basis. In 3Q17, in the US market and outside the US markets, Cialis reported revenues of $319.6 million and $245.3 million, respectively, compared to $348 million and $239 million in 3Q16. The decrease in demand of Cialis was the primary reason for the declining revenues in 3Q17.

Cialis reported YTD (year-to-date) September 2017 revenues of $1.7 billion. In the first nine months of 2017, in the US and international markets, Cialis generated revenues of $997.3 million and $728.5 million, respectively. Cialis competes with Pfizer’s (PFE) Viagra and Bayer’s (BAYZF) Levitra. In 3Q17, Viagra reported revenues of $308 million.

Effient revenue trends

In 3Q17, Effient generated revenues of $55.9 million, ~56% growth on a YoY basis and a 61% decline on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Effient reported revenues of $42.7 million and $13.1 million, respectively, compared to $112.5 million and $15.2 million in 3Q16.

Effient reported YTD September 2017 revenues of $326.6 million. In the first nine months of 2017, in the US market and outside the US market, Effient generated revenues of $290.8 million and $35.8 million, respectively.

Effient is used as a prophylaxis against blood clots in individuals with acute coronary syndrome. Effient competes with Bristol-Myers Squibb’s and Sanofi’s Plavix and AstraZeneca’s (AZN) Brilinta.

In 3Q17, Reopro generated revenues of $0.5 million compared to $21.0 million in 3Q16. In 3Q17, Eli Lilly’s cardiovascular portfolio generated revenues of $662.9 million, a ~14% decline on a YoY basis and an 18% decline on a quarter-over-quarter basis. Eli Lilly’s cardiovascular portfolio reported YTD September 2017 revenues of $2.2 billion.

The SPDR S&P 500 ETF (SPY) invests ~0.32% of its total portfolio holding in Eli Lilly.

X

Please select a profession that best describes you: